SAN DIEGO, CA, Aug. 11, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first publicly traded cannabis company in the United States to launch the world’s first cannabis-derived nutraceutical products, brands and supply chain, today announced that its pharmaceutical subsidiary, HM Pharma, has submitted a product dossier for its cannabidiol (CBD) products after receiving health authorization from ANVISA, the Brazilian Health Regulatory Agency.
According to ANVISA Regulation 327/2019, this registration allows companies like HM Pharma to import bulk crude extracts, isolated cannabinoids or finished products, as well as manufacture and distribute cannabis products to pharmacies in Brazil.
“This is a great achievement for our company and great news for the citizens of Brazil,” said Matheus Patelli, CEO of HM Pharma. “Submitting our dossier is the final step to register our product as a pharmaceutical product in Brazil which allows our company to sell our products in pharmacies. We look forward to providing another option to access the CBD for those who need it.”
HempMeds® Brasil, a subsidiary of Medical Marijuana, Inc., was the first company to legally import products into Brazil in 2015 using Brazil’s compassionate use laws. The compassionate use market in Brazil is thriving and will continue to coexist with the medical market. HempMeds® Brasil, which is currently growing 75% faster than the global Brazilian CBD market, and is the leading company in Brazil’s cannabis industry, will continue to operate under the compassionate use model, while HM Pharma will operate under ANVISA regulation 327/2019.
“It’s amazing to see continued growth and regulatory progress for our company in Brazil,” said Medical Marijuana, Inc. CEO Blake Schroeder. “We are optimistic about our incredible push into the pharmaceutical space and look forward to sharing more exciting updates on our new sales channels in the near future.”
About Medical Marijuana, Inc.
We are a firsts® company. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in obtaining the highest quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based botanical drug development and clinical research sector led by its pharmaceutical investment companies and partners, such as AXIM® Biotechnologies, Inc. and Neuropathix. Medical Marijuana, Inc. was named one of the top CBD producers by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay and is a leader in developing international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies in Mexico and Brazil to understand its safety and efficacy.
The headquarters of Medical Marijuana, Inc. is located in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To view the Medical Marijuana, Inc. corporate video, click here.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by these sections. This material contains statements about future events and/or expected financial results that are forward-looking in nature and are subject to risks and uncertainties. These forward-looking statements, by definition, involve risks, uncertainties and other factors, which may cause actual results, performance or achievements of Medical Marijuana, Inc. are materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Medical Marijuana, Inc. does not sell or distribute any product that violates the US Controlled Substances Act.
Public relations contact:
Investor Relations Contact:
P. (858) 283-4016